These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24132726)

  • 1. Skeletal manifestations of treatment of breast cancer.
    Choksi P; Williams M; Clark PM; Van Poznak C
    Curr Osteoporos Rep; 2013 Dec; 11(4):319-28. PubMed ID: 24132726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal manifestations of treatment of breast cancer on premenopausal women.
    Doo L; Shapiro CL
    Curr Osteoporos Rep; 2013 Dec; 11(4):311-8. PubMed ID: 24126616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing the risk of osteoporosis in women with a history of early breast cancer.
    Ravdin PM
    Oncology (Williston Park); 2004 Oct; 18(11):1385-90, 1393; discussion 1394. PubMed ID: 15609468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of adjuvant endocrine therapy on bone health in women with breast cancer.
    Ramchand SK; Cheung YM; Yeo B; Grossmann M
    J Endocrinol; 2019 Jun; 241(3):R111-R124. PubMed ID: 30991355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.
    Clines GA; Choksi P; Van Poznak C
    Curr Osteoporos Rep; 2015 Oct; 13(5):263-73. PubMed ID: 26209043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitor adjuvant chemotherapy of breast cancer results in cancer therapy induced bone loss.
    Rinaldi RZ
    Curr Osteoporos Rep; 2013 Mar; 11(1):61-4. PubMed ID: 23408144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
    Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone- and chemotherapy-induced bone loss in breast cancer.
    Coleman RE
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):16-20. PubMed ID: 15202583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopenia and osteoporosis in women with breast cancer.
    Ramaswamy B; Shapiro CL
    Semin Oncol; 2003 Dec; 30(6):763-75. PubMed ID: 14663777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen receptor modulators.
    Haskell SG
    South Med J; 2003 May; 96(5):469-76. PubMed ID: 12911186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hormones in cancer prevention.
    Vogel VG
    Am Soc Clin Oncol Educ Book; 2014; ():34-40. PubMed ID: 24857058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone health during endocrine therapy for cancer.
    Rachner TD; Coleman R; Hadji P; Hofbauer LC
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.
    Brufsky AM
    Curr Oncol Rep; 2008 Jan; 10(1):18-26. PubMed ID: 18366957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of breast cancer: current state of the science and future opportunities.
    Uray IP; Brown PH
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.